Oxford-AstraZeneca vaccine study shows dual immune action

Share

"These results, together with the induction of both humoral [antibodies] and cellular immune responses, support large-scale evaluation of this candidate vaccine", in ongoing Phase 3 trials, the authors wrote in the Lancet. "What this vaccine does particularly well is trigger both arms of the immune system".

"We are seeing good immune response in nearly everybody", said Dr. Adrian Hill, director of the Jenner Institute at Oxford University.

The study found that a single dose of AZD1222 resulted in a 4-fold increase in antibodies to the SARS-CoV-2 virus in 95% of participants 1 month after injection.

More than 150 potential coronavirus vaccines are in various stages of development around the world, with 23 candidates already being tested in people, according to the World Health Organization.

This is in addition to an existing agreement with AstraZeneca and the University of Oxford to research, develop and manufacture a COVID-19 vaccine for the United Kingdom public. The university is working together with the pharmaceutical company AstraZeneca, and others.

Researchers said the vaccine caused minor side effects more frequently than a control group.

State Dept: 'Disappointment' at Hagia Sophia Reverting to Mosque
A few hundred Turks carrying Turkish flags gathered outside Hagia Sophia shouting "Chains broken, Hagia Sophia reopened". For Greek Culture Minister Lina Mendoni, "the nationalism displayed by Erdogan. takes his country back six centuries".


The UK government has also agreed in principle for Valneva to supply 60 million doses of a vaccine it is developing, and a further 40 million if it's found to be "safe, effective and suitable".

In the study conducted in Germany on 60 healthy volunteers, the vaccine induced virus-neutralising antibodies in those given two doses, in-line with previous results from an early-stage U.S. trial.

Oxford scientists behind the trial have said the preliminary results are "very encouraging", while Boris Johnson has said it is an "important step in the right direction". A separate trial in China involving more than 500 people showed that most had developed widespread antibody immune response.

"However, we need more research before we can confirm the vaccine effectively protects against SARS-CoV-2 (COVID-19) infection, and for how long any protection lasts". Results from testing in animals had already shown the Oxford-AstraZeneca shot provoked an immune response. This preview is then supposed to induce a protective response against the virus that should prepare the immune system for the real deal.

British researchers first tested the vaccine on about 1,000 people in April, half of whom were given the dose and the other half a placebo, AP reported. The spike protein is the one used by the virus to invade our cells.

Share